5-APDI

Indanylaminopropane
Clinical data
Other names1-(5-indanyl)-2-aminopropane
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
Identifiers
  • (±)-1-(2,3-dihydro-1H-inden-5-yl)propan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H17N
Molar mass175.275 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • c1cc(cc2c1CCC2)CC(N)C
  • InChI=1S/C12H17N/c1-9(13)7-10-5-6-11-3-2-4-12(11)8-10/h5-6,8-9H,2-4,7,13H2,1H3 checkY
  • Key:QYVNZHBQYJRLEX-UHFFFAOYSA-N checkY
  (verify)

5-(2-Aminopropyl)-2,3-dihydro-1H-indene (5-APDI), also known as indanylaminopropane (IAP), IAP (psychedelic), 2-API(2-aminopropylindane), indanametamine, and, incorrectly, as indanylamphetamine,[1] is an entactogen and psychedelic drug of the amphetamine family.[2][3] It has been sold by online vendors through the Internet and has been encountered as a designer drug since 2003,[1] but its popularity and availability has diminished in recent years.

5-APDI acts as a potent and weakly selective serotonin releasing agent (SSRA) with IC50 values of 82 nM, 1,848 nM, and 849 nM for inhibiting the reuptake of serotonin, dopamine, and norepinephrine, respectively.[2][3] It fully substitutes for MBDB but not amphetamine in trained animals, though it does produce disruption for the latter at high doses.[2]

5-APDI has been classified as a class B drug under the Misuse of Drugs Act 1971 since 10 June 2014.

See also

References

  1. ^ a b Casale JF, McKibben TD, Bozenko JS, Hays PA (2005). "Characterization of the "Indanylamphetamines"". Microgram Journal. 3 (1–2): 3–10. Archived from the original on 2009-03-17. Retrieved 2009-08-06.
  2. ^ a b c Monte AP, Marona-Lewicka D, Cozzi NV, Nichols DE (November 1993). "Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine". Journal of Medicinal Chemistry. 36 (23): 3700–6. doi:10.1021/jm00075a027. PMID 8246240.
  3. ^ a b Parker MA, Marona-Lewicka D, Kurrasch D, Shulgin AT, Nichols DE (March 1998). "Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-(methylenedioxy)amphetamine (MDA)". Journal of Medicinal Chemistry. 41 (6): 1001–5. CiteSeerX 10.1.1.688.9559. doi:10.1021/jm9705925. PMID 9526575.